CAJ | 학술논문

目的：探讨富含AT序列特异性结合蛋白2(special AT-rich sequence-binding protein 2, SATB2)在结直肠癌组织及对应淋巴结转移灶中的表达,并分析其与临床病理特征的关系。方法应用免疫组化EnVision法检测200例结直肠癌原发灶及80例淋巴结转移灶中SATB2蛋白表达。结果结直肠癌原发灶中SATB2高表达率为25．0%(50/200),中等强度表达率为36．0%(72/200),阴性率为39．0%(78/200)。对应淋巴结转移灶中SATB2高表达率为15．0%(12/80),中等强度表达率为28．8%(23/80),阴性率为56．2%(45/80)。 SATB2在结直肠癌原发灶中的表达与肿瘤大小、分化程度,浸润深度、淋巴结转移以及TNM分期显著相关(P<0．05),与患者年龄、性别及远处转移无相关性。 SATB2在结直肠癌淋巴结转移灶中表达显著低于原发灶(P<0．05),其在转移灶中的表达与临床病理因素无明显相关性。结论 SATB2低表达与结直肠癌的发生、发展相关,在肿瘤转移过程中表达明显降低,有望成为新型的结直肠癌分子靶标。
목적：탐토부함AT서렬특이성결합단백2(special AT-rich sequence-binding protein 2, SATB2)재결직장암조직급대응림파결전이조중적표체,병분석기여림상병리특정적관계。방법응용면역조화EnVision법검측200례결직장암원발조급80례림파결전이조중SATB2단백표체。결과결직장암원발조중SATB2고표체솔위25．0%(50/200),중등강도표체솔위36．0%(72/200),음성솔위39．0%(78/200)。대응림파결전이조중SATB2고표체솔위15．0%(12/80),중등강도표체솔위28．8%(23/80),음성솔위56．2%(45/80)。 SATB2재결직장암원발조중적표체여종류대소、분화정도,침윤심도、림파결전이이급TNM분기현저상관(P<0．05),여환자년령、성별급원처전이무상관성。 SATB2재결직장암림파결전이조중표체현저저우원발조(P<0．05),기재전이조중적표체여림상병리인소무명현상관성。결론 SATB2저표체여결직장암적발생、발전상관,재종류전이과정중표체명현강저,유망성위신형적결직장암분자파표。
Purpose To investigate the special AT-rich sequence-binding protein 2 ( SATB2 ) expression in colorectal cancer tissues and metastatic lymph nodes. Methods Immunohistochemistry was used to detect the expression of SATB2 protein in 200 cases of colorectal cancer and 80 cases of correspondence metastatic lymph nodes. Results The ratio of high, intermediate and negative SATB2 expression were 25. 0%(50/200), 36. 0%(72/200) and 39. 0%(78/200) respectively. The high, intermediate and negative expression ratio of SATB2 in corresponding metastatic lymph nodes were 15. 0%( 12/80 ) , 28. 8%( 23/80 ) , 56. 2%( 45/80 ) . Ex-pression of SATB2 was significantly associated with tumor size, differentiation, invasion depth, lymph node metastasis and TNM stages (P<0. 05), while not with age, gender and distant metastasis. The expression of SATB2 in metastatic lymph nodes was significantly lower than that in primary lesion (P<0. 05). But the expression of SATB2 in metastatic lymph nodes had no relationship with clinico-pathologic characteristics. Conclusion Low expression of SATB2 was associated with the development and progression of colorectal cancer. The expression of SATB2 was significantly down-regulated in the metastatic lymph nodes. SATB2 will be a new hopeful molec-ular marker of CRC.